Fosmetpantotenate Randomized Controlled Trial in Pantothenate Kinase-Associated Neurodegeneration.
fosmetpantotenate
pantothenate kinase-associated neurodegeneration
randomized controlled trial
treatment
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
20
10
2020
received:
18
07
2020
accepted:
26
10
2020
pubmed:
18
11
2020
medline:
24
6
2021
entrez:
17
11
2020
Statut:
ppublish
Résumé
Pantothenate kinase-associated neurodegeneration (PKAN) currently has no approved treatments. The Fosmetpantotenate Replacement Therapy pivotal trial examined whether treatment with fosmetpantotenate improves PKAN symptoms and stabilizes disease progression. This randomized, double-blind, placebo-controlled, multicenter study evaluated fosmetpantotenate, 300 mg oral dose three times daily, versus placebo over a 24-week double-blind period. Patients with pathogenic variants of PANK2, aged 6 to 65 years, with a score ≥6 on the PKAN-Activities of Daily Living (PKAN-ADL) scale were enrolled. Patients were randomized to active (fosmetpantotenate) or placebo treatment, stratified by weight and age. The primary efficacy endpoint was change from baseline at week 24 in PKAN-ADL. Between July 23, 2017, and December 18, 2018, 84 patients were randomized (fosmetpantotenate: n = 41; placebo: n = 43); all 84 patients were included in the analyses. Six patients in the placebo group discontinued treatment; two had worsening dystonia, two had poor compliance, and two died of PKAN-related complications (aspiration during feeding and disease progression with respiratory failure, respectively). Fosmetpantotenate and placebo group PKAN-ADL mean (standard deviation) scores were 28.2 (11.4) and 27.4 (11.5) at baseline, respectively, and were 26.9 (12.5) and 24.5 (11.8) at week 24, respectively. The difference in least square mean (95% confidence interval) at week 24 between fosmetpantotenate and placebo was -0.09 (-1.69 to 1.51; P = 0.9115). The overall incidence of treatment-emergent serious adverse events was similar in the fosmetpantotenate (8/41; 19.5%) and placebo (6/43; 14.0%) groups. Treatment with fosmetpantotenate was safe but did not improve function assessed by the PKAN-ADL in patients with PKAN. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Sections du résumé
BACKGROUND
Pantothenate kinase-associated neurodegeneration (PKAN) currently has no approved treatments.
OBJECTIVES
The Fosmetpantotenate Replacement Therapy pivotal trial examined whether treatment with fosmetpantotenate improves PKAN symptoms and stabilizes disease progression.
METHODS
This randomized, double-blind, placebo-controlled, multicenter study evaluated fosmetpantotenate, 300 mg oral dose three times daily, versus placebo over a 24-week double-blind period. Patients with pathogenic variants of PANK2, aged 6 to 65 years, with a score ≥6 on the PKAN-Activities of Daily Living (PKAN-ADL) scale were enrolled. Patients were randomized to active (fosmetpantotenate) or placebo treatment, stratified by weight and age. The primary efficacy endpoint was change from baseline at week 24 in PKAN-ADL.
RESULTS
Between July 23, 2017, and December 18, 2018, 84 patients were randomized (fosmetpantotenate: n = 41; placebo: n = 43); all 84 patients were included in the analyses. Six patients in the placebo group discontinued treatment; two had worsening dystonia, two had poor compliance, and two died of PKAN-related complications (aspiration during feeding and disease progression with respiratory failure, respectively). Fosmetpantotenate and placebo group PKAN-ADL mean (standard deviation) scores were 28.2 (11.4) and 27.4 (11.5) at baseline, respectively, and were 26.9 (12.5) and 24.5 (11.8) at week 24, respectively. The difference in least square mean (95% confidence interval) at week 24 between fosmetpantotenate and placebo was -0.09 (-1.69 to 1.51; P = 0.9115). The overall incidence of treatment-emergent serious adverse events was similar in the fosmetpantotenate (8/41; 19.5%) and placebo (6/43; 14.0%) groups.
CONCLUSIONS
Treatment with fosmetpantotenate was safe but did not improve function assessed by the PKAN-ADL in patients with PKAN. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Identifiants
pubmed: 33200489
doi: 10.1002/mds.28392
pmc: PMC8246547
doi:
Substances chimiques
Pantothenic Acid
19F5HK2737
fosmetpantotenate
VA101M0K2F
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1342-1352Informations de copyright
© 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Références
Mov Disord. 2011 Aug 1;26(9):1756-9
pubmed: 21557313
Hum Mol Genet. 2003 Feb 1;12(3):321-7
pubmed: 12554685
Ann Neurol. 2006 Feb;59(2):248-56
pubmed: 16437574
Nat Genet. 2001 Aug;28(4):345-9
pubmed: 11479594
PLoS One. 2018 Mar 9;13(3):e0192028
pubmed: 29522513
Mol Genet Metab. 2017 Mar;120(3):278-287
pubmed: 28034613
J Exp Neurosci. 2019 May 23;13:1179069519851118
pubmed: 31205425
Nat Commun. 2018 Oct 23;9(1):4399
pubmed: 30352999
Dev Med Child Neurol. 2010 Jun;52(6):570-5
pubmed: 20132143
Mov Disord. 2008 Nov 15;23(15):2129-70
pubmed: 19025984
J Neurosci. 2005 Jan 19;25(3):689-98
pubmed: 15659606
EMBO Mol Med. 2019 Dec;11(12):e10489
pubmed: 31660701
Handb Clin Neurol. 2018;147:293-305
pubmed: 29325618
Annu Rev Genomics Hum Genet. 2015;16:257-79
pubmed: 25973518
J Inherit Metab Dis. 2019 Jan;42(1):49-56
pubmed: 30740736
J Med Genet. 2009 Feb;46(2):73-80
pubmed: 18981035
Biochem Soc Trans. 2014 Aug;42(4):1069-74
pubmed: 25110004
Dev Med Child Neurol. 1999 Jun;41(6):404-11
pubmed: 10400175
Orphanet J Rare Dis. 2019 Jul 12;14(1):174
pubmed: 31300018
Clin Trials. 2019 Aug;16(4):410-418
pubmed: 31055958
Biochem Soc Trans. 2014 Aug;42(4):1063-8
pubmed: 25110003
Lancet Neurol. 2019 Jul;18(7):631-642
pubmed: 31202468
Mov Disord Clin Pract. 2019 Jan 22;6(2):139-149
pubmed: 30838313
Case Rep Neurol Med. 2017;2017:3247034
pubmed: 28567317
Prog Lipid Res. 2005 Mar-May;44(2-3):125-53
pubmed: 15893380
N Engl J Med. 2003 Jan 2;348(1):33-40
pubmed: 12510040